Granules India (GRANULES.NS) Osake Kurssi
Granules India Kurssi
Viimeisten 19 vuoden aikana Granules Indian liikevaihto kasvoi 18,5 % vuodessa ja ylsi 44,82 Mrd. INR:een. Osakekohtainen tulos on kasvanut 21,1 % vuodessa viimeisten 19 vuoden aikana. Granules Indian nettomarginaali 11,2 % on laskenut verrattuna 17,0 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 0,18 %. Jakosuhde on noin 7 % tuloksesta. Osinko on kasvanut 15,7 % vuodessa viimeisten 17 vuoden aikana. Granules Indian 12 kuukauden konsensustavoitehinta on 644,64 INR, noin ali kurssia 22,4 %. 13 analyytikosta 11 suosittaa ostoa — kokonaiskonsensus on Osta.
Granules India osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Granules India liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Granules India -osakkeesta
Granules India Ltd operates under a business model that focuses on pharmaceutical manufacturing. The company specializes in the production and distribution of active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI). With an extensive portfolio of products, Granules India Ltd caters to both domestic and international markets. By leveraging their strong research and development capabilities, the company ensures the highest quality standards in drug manufacturing. Granules India Ltd's commitment to innovation and customer-centric approach has established them as a leading player in the pharmaceutical industry.
Granules India Ltd is primarily active in the pharmaceutical industry. With its focus on manufacturing and exporting pharmaceutical products, the company plays a crucial role in the healthcare sector. Granules India Ltd has established itself as a leading player in the global pharmaceutical market, providing high-quality active pharmaceutical ingredients (APIs), intermediates, and finished dosages to customers worldwide. The company's commitment to innovation, quality, and customer satisfaction has contributed to its success and growth in the highly competitive pharmaceutical industry. Granules India Ltd continuously strives to meet the healthcare needs of patients by providing affordable and effective medicines.
The main competitors of Granules India Ltd in the market include Aurobindo Pharma Ltd, Divis Laboratories Ltd, and Dr. Reddy's Laboratories Ltd.
Granules India Ltd is a leading pharmaceutical company that specializes in the manufacturing and marketing of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs). Established in 1984, Granules India Ltd has grown exponentially over the years and is now recognized as one of India's largest vertically integrated pharmaceutical manufacturers. With a strong focus on research and development, Granules India Ltd has successfully developed and commercialized numerous products for various therapeutic segments. The company's commitment to quality, innovation, and customer satisfaction has positioned it as a trusted global player in the pharmaceutical industry. Granules India Ltd continues to expand its product portfolio and strengthen its presence in both domestic and international markets.
Granules India Ltd has achieved several significant milestones in its journey. The company has successfully established itself as a leading manufacturer of pharmaceutical formulation intermediates (PFIs) and active pharmaceutical ingredients (APIs). With a focus on innovation and quality, Granules India Ltd has received multiple certifications, including EU GMP and US FDA approvals for its manufacturing units. The company has also expanded its presence globally, with a strong customer base across various countries. Additionally, Granules India Ltd has consistently shown robust financial performance, with steady revenue growth and improved profitability. These achievements highlight the company's commitment to excellence and make it a trusted name in the pharmaceutical industry.
Granules India Ltd is primarily present in India, as it is an Indian pharmaceutical company. It has established a strong presence in the domestic market and has been serving the healthcare needs of millions of people in the country. With its state-of-the-art manufacturing facilities located across various regions in India, Granules India Ltd has successfully catered to the growing demand for high-quality pharmaceutical products. Additionally, the company has also expanded its global footprint and has a significant presence in several countries worldwide, including the United States, Europe, and Asia, through its diverse customer base and strategic partnerships.
Granules India Ltd represents values of integrity, quality, and patient-centricity. With a corporate philosophy focused on innovation and customer satisfaction, the company strives to provide cost-effective and high-quality pharmaceutical products. Granules India Ltd emphasizes on continuous improvement, ethical business practices, and delivering value to all stakeholders. The company's commitment to research, development, and regulatory compliance highlights its dedication to providing safe and effective healthcare solutions. Through its customer-centric approach and consistent growth, Granules India Ltd has established itself as a leading player in the pharmaceutical industry.
Analyytikot asettavat tällä hetkellä Granules India-osakkeelle keskimääräisen tavoitehinnan 643,62 INR (mediaani: 644,64 INR), mikä merkitsee −22,5 % viimeisimpään hintaan verrattuna. Konsensus perustuu 13 analyytikkoarvioon.
13 analyytikkoa arvioi tällä hetkellä Granules India-osaketta: 11 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Granules India-yhtiöltä 53,08 Mrd. INR liikevaihtoa ja 24,37 INR osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Granules India-osake noteerataan hintaan 7,84 EUR (830,55 INR).
Granules India-osake (GRANULES.NS) on listattuna 2 pörssissä, muun muassa: NSE (Indien) (GRANULES.NS).
Granules India Ltd is a leading company in the pharmaceutical active ingredient and formulation industry, headquartered in Hyderabad, India. It started as a small company in 1984 and has grown into a multinational company operating in over 60 countries. The business areas of Granules India include pharmaceutical active ingredients, dosage forms, research and development, as well as equipment and supplies. The company is a major player in the manufacturing of generic drugs, which provide a cost-effective alternative to more expensive patented medications. Pharmaceutical active ingredients: Granules India produces a wide range of pharmaceutical active ingredients used in various medical applications, including pain management, metabolic disorders, cardiovascular and infectious diseases. The company has a strong expertise in manufacturing active ingredients for novel drugs and offers a wide range of products in different therapy areas. Dosage forms: The company also produces a variety of dosage forms such as tablets, capsules, granules, and powders, which allow for the delivery of active ingredients in the desired quantity and dosage to the patient. Granules India works closely with its customers to develop customized solutions for their specific requirements. Research and development: Granules India maintains an extensive research and development department specializing in the development and manufacturing of novel active ingredients and formulations. The company is committed to seeking new technologies and techniques to produce better pharmaceutical products that are more effective and safer. Equipment and supplies: Granules India also has a department for equipment and supplies that support the manufacturing of pharmaceutical products. They manufacture machines and equipment used by other pharmaceutical companies to produce their products. They also offer specialized services such as installation, maintenance, and repair of these equipment. Granules India is also a key player in the development of biosimilars approved by the Food and Drug Administration (FDA). The company also develops and manufactures topical medications such as ointments, gels, and creams, which treat skin issues and infections. Overall, Granules India has an impressive business model and offers a wide range of pharmaceutical products and services. The company has focused on quality, collaboration, and innovation, and is able to provide tailored solutions to its customers' specific needs.
odotettu liikevaihto Granules India on 53,08 Mrd. INR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Granules India on 5,91 Mrd. INR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Granules India:n hinta-voitto-suhde (P/E) on tällä hetkellä 34,08. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Granules India-osakkeen arvostusta.
Granules India:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,80. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Granules India-osakkeen arvostuskennuslukuna.
Granules India:n Eulpool-laatuscore on 8/10.
Granules India:n ISIN on INE101D01020. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Granules India:n ticker on GRANULES.NS. Tämä pörssinoteeraus käytetään Granules India-osakkeiden kauppaan pörssissä.
Granules India osake
Granules India vertaisryhmä
Granules India Ticker
Granules India FIGI
Kaikki tunnusluvut ja syvällinen analyysi Granules India:sta
Meidän osakeanalyysimme Granules India-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Granules India:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: